Commit and Keratoconus - a phase IV clinical study of FDA data
Summary:
We study 5,610 people who take Commit (nicotine polacrilex) or have Keratoconus. No report of Keratoconus is found in people who take Commit.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Commit?
Commit has active ingredients of nicotine polacrilex. eHealthMe is studying from 4,842 Commit users. Check the latest studies of Commit.
What is Keratoconus?
Keratoconus (a condition in which your eye's cornea is unable to hold its round shape) is found to be associated with 22 drugs and 204 conditions by eHealthMe. Check the latest studies of Keratoconus.
No report is found.
Do you take Commit and have Keratoconus?
- Check whether Keratoconus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Commit:
- Commit (4,842 reports)
Keratoconus treatments and more:
- Keratoconus (768 reports)
How severe was Keratoconus and when was it recovered:
Expand to all the drugs that have ingredients of nicotine polacrilex:
Browse all side effects of Commit:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Keratoconus:
Browse all the conditions that are associated with Keratoconus:
How the study uses the data?
The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Commit) and Commit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Joint Crepitation and drugs of ingredients of tramadol hydrochloride - 6 seconds ago
- Drug interactions of Adenosylmethionine and Adderall - 8 seconds ago
- Could Northera cause Blood Pressure Abnormal? - 10 seconds ago
- Drug interactions of Acyclovir and Sulfamethoxazole And Trimethoprim - 17 seconds ago
- Drug interactions of Zenpep and Geodon - 19 seconds ago
- Drug interactions of Triamcinolone Acetonide and Adcal - 25 seconds ago
- Solu-Medrol and Hair Thinning for Women aged 30-39 - 32 seconds ago
- Solu-Medrol and Loss Of Hair for Women aged 30-39 - 33 seconds ago
- Solu-Medrol and Hairloss for Women aged 30-39 - 33 seconds ago
- Solu-Medrol and Baldness for Women aged 30-39 - 33 seconds ago